1147-98-4

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide is used as a research compound for exploring its potential biological activities. It is employed in the development of new drugs, targeting a range of diseases and conditions due to its unique chemical structure and functional groups.
Used in Chemical and Biochemical Research:
In the realm of chemical and biochemical research, 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide serves as a reference compound. It is utilized to investigate the structure-activity relationships of related molecules, providing insights into the design and optimization of new chemical entities with improved therapeutic properties.
Used in Drug Development:
5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide is used as a lead compound in drug development. Its structure and properties make it a candidate for the creation of new pharmaceuticals, potentially offering novel treatment options for various medical conditions.
Used in Chemical Synthesis:
5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide may also be used as an intermediate in the synthesis of other related chemical entities, contributing to the advancement of chemical libraries and the discovery of new therapeutic agents.

InChI:InChI=1/C13H9Cl2NO2/c14-8-1-4-10(5-2-8)16-13(18)11-7-9(15)3-6-12(11)17/h1-7,17H,(H,16,18)

Upstream product

• 87-17-2 salicylanilide 
• 71-43-2 benzene 
• 15216-81-6 5-chloro-2-hydroxybenzoyl chloride 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 20972-98-9 6-chloro-3-(4-chloro-phenyl)-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 17893-02-6 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl acetate 
• 1422904-25-3 C₂₀H₁₃Cl₂NO₃ 
• 1552270-27-5 4-chloro-2-[(4-chlorophenyl)carbamoyl]phenyl diethyl phosphate 
• 1403607-21-5 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl 4-(trifluoromethyl)benzoate 
• 1426258-41-4 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate 
• 1219818-86-6 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl undecylcarbamate 
• 1219818-85-5 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl decylcarbamate 
• 1219818-84-4 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl nonylcarbamate 
• 1219818-83-3 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl octylcarbamate 
• 1219818-82-2 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl heptylcarbamate 
• 1219818-81-1 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl hexylcarbamate 
• 1219818-80-0 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl pentylcarbamate 
• 1227476-97-2 C₂₂H₁₈Cl₂N₂O₃ 

Relevant academic research and scientific papers

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection

Zika virus has emerged as a potential threat to human health globally. A previous drug repurposing screen identified the approved anthelminthic drug niclosamide as a small molecule inhibitor of Zika virus infection. However, as antihelminthic drugs are generally designed to have low absorption when dosed orally, the very limited bioavailability of niclosamide will likely hinder its potential direct repurposing as an antiviral medication. Here, we conducted SAR studies focusing on the anilide and salicylic acid regions of niclosamide to improve physicochemical properties such as microsomal metabolic stability, permeability and solubility. We found that the 5-bromo substitution in the salicylic acid region retains potency while providing better drug-like properties. Other modifications in the anilide region with 2′-OMe and 2′-H substitutions were also advantageous. We found that the 4′-NO2 substituent can be replaced with a 4′-CN or 4′-CF3 substituents. Together, these modifications provide a basis for optimizing the structure of niclosamide to improve systemic exposure for application of niclosamide analogs as drug lead candidates for treating Zika and other viral infections. Indeed, key analogs were also able to rescue cells from the cytopathic effect of SARS-CoV-2 infection, indicating relevance for therapeutic strategies targeting the COVID-19 pandemic.

CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE

Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.